The nuclear export protein XPO1—from biology to targeted therapy

AS Azmi, MH Uddin, RM Mohammad - Nature reviews Clinical oncology, 2021 - nature.com
Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

[HTML][HTML] Diffuse large B-cell lymphoma: new targets and novel therapies

BD Cheson, G Nowakowski, G Salles - Blood cancer journal, 2021 - nature.com
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with
diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved …

[HTML][HTML] Revisiting Richter transformation in the era of novel CLL agents

A Petrackova, P Turcsanyi, T Papajik, E Kriegova - Blood Reviews, 2021 - Elsevier
Richter transformation (RT) is the development of aggressive lymphoma–most frequently
diffuse large B-cell lymphoma (DLBCL) and rarely Hodgkin lymphoma (HL)–arising on the …

FDA approval summary: selinexor for relapsed or refractory diffuse large B-cell lymphoma

YL Kasamon, LSL Price, OO Okusanya… - The …, 2021 - academic.oup.com
Abstract In June 2020, the US Food and Drug Administration granted accelerated approval
to selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell …

Investigational drugs for the treatment of diffuse large B-cell lymphoma

A Patriarca, G Gaidano - Expert Opinion on Investigational Drugs, 2021 - Taylor & Francis
Introduction: Diffuse large B cell lymphoma (DLBCL) is the most frequent lymphoma in
adults. 30–40% DLBCL eventually relapse and 10% are primary refractory, posing an unmet …

Selinexor in combination with R-CHOP for frontline treatment of non-hodgkin lymphoma: results of a phase I study

EK Seymour, HY Khan, Y Li, M Chaker, I Muqbil… - Clinical Cancer …, 2021 - AACR
Purpose: The nuclear exporter protein exportin-1 (XPO1) is overexpressed in non-Hodgkin
lymphoma (NHL) and correlates with poor prognosis. We evaluated enhancing R-CHOP …

Chromosome region maintenance 1 (XPO1/CRM1) as an anticancer target and discovery of its inhibitor

S Liu, W Qiao, Q Sun, Y Luo - Journal of Medicinal Chemistry, 2021 - ACS Publications
Chromosome region maintenance 1 (CRM1) is a major nuclear export receptor protein and
contributes to cell homeostasis by mediating the transport of cargo from the nucleus to the …

Pharmacokinetics of selinexor: the first-in-class selective inhibitor of nuclear export

JC Bader, AR Abdul Razak, S Shacham, H Xu - Clinical Pharmacokinetics, 2021 - Springer
The functionality of many tumor suppressor proteins (TSPs) and oncoprotein transcript RNAs
largely depend on their location within the cell. The exportin 1 complex (XPO1) transports …

[HTML][HTML] JAK3 is expressed in the nucleus of malignant T cells in cutaneous T cell lymphoma (CTCL)

CK Vadivel, M Gluud, S Torres-Rusillo, L Boding… - Cancers, 2021 - mdpi.com
Simple Summary JAK3 plays an important role in the pathogenesis of cutaneous T cell
lymphoma. JAK3 belongs to the Janus kinase family of receptor-associated tyrosine kinases …

[HTML][HTML] Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies

S Wang, L Sellner, L Wang, T Sauer… - Oncology …, 2021 - spandidos-publications.com
Chimeric antigen receptor (CAR) T cells directed against CD19 (CD19. CAR T cells) have
yielded impressive clinical responses in the treatment of patients with lymphoid …